Simmons Bank Grows Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Simmons Bank boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 9.2% during the 3rd quarter, Holdings Channel.com reports. The firm owned 4,095 shares of the medical device company’s stock after acquiring an additional 345 shares during the period. Simmons Bank’s holdings in DexCom were worth $275,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Canada Pension Plan Investment Board increased its holdings in DexCom by 189.1% in the second quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock valued at $75,471,000 after buying an additional 435,401 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of DexCom by 53.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock worth $66,352,000 after acquiring an additional 345,114 shares in the last quarter. Bellevue Group AG lifted its stake in DexCom by 33.5% during the first quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock worth $169,380,000 after purchasing an additional 306,604 shares during the last quarter. Finally, Magnetar Financial LLC acquired a new position in DexCom in the second quarter valued at approximately $31,793,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Stifel Nicolaus raised their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Sanford C. Bernstein upped their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. BTIG Research decreased their target price on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, Robert W. Baird lifted their price target on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $74.68 on Friday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a 50-day moving average price of $69.77 and a 200 day moving average price of $92.14. The company has a market cap of $29.17 billion, a P/E ratio of 44.72, a PEG ratio of 2.28 and a beta of 1.17. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Insider Activity

In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.